This Circular sets forth the economic and technical characteristics of opioid drug dependence treatment services using methadone and other measures at public service units. It applies to public health units, related organizations, and individuals.
적용 범위
Public service units providing opioid drug dependence treatment services and related organizations and individuals
핵심 사항
- Public service units must comply with the economic and technical characteristics of opioid drug dependence treatment services using methadone (Article 2).
- Initial examination, during treatment, and completion of treatment services are specified in detail regarding their names, types, and categories (Point 1, Article 2).
- Pre-treatment, during-treatment, and post-treatment individual counseling and psychological therapy are clearly defined (Point 2, Article 2).
- Daily or multi-day methadone dispensing at the treatment facility or elsewhere is specifically detailed (Point 3, Article 2).
- Ancillary clinical services such as laboratory tests, imaging, functional assessments, and psychological testing have specific requirements (Point 4, Article 2).
🌐 이 문서의 사회적 영향
- Enhance the effectiveness of opioid drug dependence treatment.
- Reduce financial burden on patients through specific regulations on services and costs.
- Public health units have additional guidelines to implement services more professionally.
❓ 자주 묻는 질문
What does opioid drug dependence treatment service include?
It includes initial examination, examination during treatment, and completion of treatment; pre-treatment, during-treatment, and post-treatment individual counseling; daily or multi-day methadone dispensing.
Which ancillary clinical services are specified?
They include blood tests such as complete blood count, biochemistry, rapid opiate detection in urine; imaging and functional tests like chest X-ray, electrocardiogram.
Who is responsible for implementing this Circular?
The Director of the Department of HIV/AIDS Prevention and Control, the Head of the Department of Planning and Finance, and the Heads of units under and affiliated with the Ministry of Health; the Directors of Provincial Health Services.
When does this Circular take effect?
From December 15, 2024
전문
|
MINISTRY OF HEALTH |
SOCIALIST REPUBLIC OF VIET NAM |
|
Number: 26/2024/TT-BYT |
Hanoi, October 31, 2024 |
CIRCULAR
REGULATIONS ON ECONOMIC AND TECHNICAL CHARACTERISTICS OF SERVICES FOR THE TREATMENT OF DRUG ADDICTION IN THE FORM OF NARCOTIC SUBSTANCES AT PUBLIC ENTERPRISE UNITS
FORM OF THE DRUG CURRENTLY IMPLEMENTED BY PUBLIC ENTERPRISE UNITS
_________________
THE MINISTER OF HEALTH
Pursuant to the Law on Prices dated June 19, 2023;
Pursuant to Decree No. 85/2024/NĐ-CP dated July 10, 2024 of the Government detailing certain provisions of the Law on Prices;
Pursuant to Decree No. 95/2022/NĐ-CP dated November 15, 2022 of the Government stipulating the functions, tasks, powers, and organizational structure of the Ministry of Health;
Pursuant to the proposal of the Director of the HIV/AIDS Prevention and Control Department;
The Minister of Health issues this Circular regulating the economic and technical characteristics of services for the treatment of drug addiction in the form of narcotic substances at public enterprise units.
Article 1. Scope of Regulation and Applicability
Article 1. This Circular regulates the economic and technical characteristics of services for the treatment of drug addiction in the form of narcotic substances at public enterprise units.
Article 2. This Circular applies to public enterprise units providing services for the treatment of drug addiction in the form of narcotic substances and related organizations and individuals.
Article 2. Economic and Technical Characteristics of Services for the Treatment of Drug Addiction in the Form of Narcotic Substances
Clause 1. The economic and technical characteristics of services for the treatment of drug addiction in the form of narcotic substances using methadone include detailed names and specific types as follows:
|
Serial number |
Detailed name |
Specific Types |
|
|
1 |
1.1 |
Initial Examination |
Examination and Treatment of Drug Addiction in the Form of Narcotic Substances Using Methadone |
|
1.2 |
Dosage Adjustment Examination |
||
|
1.3 |
Examination During Treatment Process |
||
|
1.4 |
Completion Examination After Treatment |
||
|
1.5 |
Acute Opioid Poisoning Treatment |
||
|
2 |
2.1 |
Individual Counseling Before Treatment |
Psychological Therapy (only counseling method) during the treatment of drug addiction in the form of narcotic substances using methadone |
|
2.2 |
Individual Counseling During Treatment Process |
||
|
2.3 |
Individual Counseling After Completion of Treatment |
||
|
2.4 |
Group Psychological Therapy (patient or family) |
||
|
3 |
3.1 |
Daily Medication Dispensing at Treatment Facility |
Methadone Dispensing |
|
3.2 |
Daily Medication Dispensing at Medication Dispensing Facility |
||
|
3.3 |
Multi-day Medication Dispensing at Treatment Facility |
||
|
3.4 |
Multi-day Medication Dispensing at Medication Dispensing Facility |
||
|
4 |
4.1 |
Clinical Laboratory Tests: - Complete Blood Count (by manual method, automated hematology analyzer, laser-based system, or fully automated system); - Biochemistry: Measurement of ALT (GPT) activity; Measurement of AST (GOT) activity; Quantification of Glucose...; - Rapid Opiate Urine Test; - Rapid HIV Ag/Ab Test. |
Clinical Laboratory Tests |
|
4.2 |
Clinical Imaging and Functional Tests: - Chest X-ray; - Routine Electrocardiogram; - Abdominal Ultrasound (liver, gallbladder, pancreas, spleen, kidneys, bladder). |
||
|
4.3 |
Clinical Psychological Testing |
||
|
4.4 |
Other Clinical Tests: Performed according to the physician's instructions for diagnosis and treatment. |
||
Clause 2. The economic and technical characteristics of services for the treatment of drug addiction in the form of narcotic substances using other methods shall be implemented in accordance with the laws on diagnosis and treatment.
Article 3. Effectiveness
This Circular takes effect from December 15, 2024.
Article 4. Responsibilities for Implementation
The Director of the HIV/AIDS Prevention and Control Department, the Director of the Planning and Finance Department, and the heads of units under and affiliated with the Ministry of Health; the Directors of Provincial Health Departments and central city health departments, and relevant agencies, organizations, and individuals are responsible for implementing this Circular.
In the course of implementation, if there are difficulties or obstacles, agencies, organizations, and individuals are requested to promptly report to the Ministry of Health (HIV/AIDS Prevention and Control Department) for consideration and resolution./.
|
Place of Receipt: |
DEPUTY MINISTER |
원본 문서(PDF)
관계도
문서를 클릭하면 열립니다. 빨간 테두리＝효력을 변경하는 관계.
번역본
이 문서는 다음 언어로 제공됩니다: